Document Detail


Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma.
MedLine Citation:
PMID:  8275205     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To determine whether treatment regimens for unopposed estrogens can be tailored so as to minimize the excess risk of endometrial cancer, results from 19 published studies of the association between unopposed estrogen use and endometrial cancer were compiled. We sought to examine the influence of duration of use, recency, dose, type of estrogen preparation, and periodic interruption of use on cancer incidence. Estrogen use for 5 years or longer was examined in 18 studies and was associated with a large increase in the risk of endometrial cancer in each one (range in relative risk, 1.8 to 36). Use for shorter durations also was observed to increase risk; however, among women who used estrogens for less than 6 months, any increased risk that may exist appears to be very small in size (six studies; range, 0.6 to 1.4). Risk consistently was seen to decrease with increasing time since cessation of use, although there is evidence from seven of eight studies that some residual excess risk remains long after estrogens have been discontinued. In each of 12 studies that examined the influence of dose, all dose levels of conjugated estrogens increased risk of endometrial cancer substantially. Four of five studies found no differences between oral synthetic estrogens and conjugated estrogens with respect to cancer risk, and all of eight studies found no difference between cyclic and continuous regimens. Based on our review, we conclude that apart from minimizing the duration of use, there is no way of taking unopposed postmenopausal estrogens that reduces their potential to cause endometrial cancer.
Authors:
L J Herrinton; N S Weiss
Related Documents :
16785155 - The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an ...
966135 - Estrogens, lactation and oral glucose tolerance test in the early puerperium.
9618795 - Dhea and the intracrine formation of androgens and estrogens in peripheral target tissu...
17030475 - Preliminary evidence that long-term estrogen use reduces white matter loss in aging.
19102955 - Clinical and angiographic characteristics of premenopausal women with coronary artery d...
9685525 - Lateral spine densitometry in obese women.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of epidemiology     Volume:  3     ISSN:  1047-2797     ISO Abbreviation:  Ann Epidemiol     Publication Date:  1993 May 
Date Detail:
Created Date:  1994-02-10     Completed Date:  1994-02-10     Revised Date:  2008-06-23    
Medline Journal Info:
Nlm Unique ID:  9100013     Medline TA:  Ann Epidemiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  308-18     Citation Subset:  IM    
Affiliation:
Department of Epidemiology, University of Washington, Seattle.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Endometrial Neoplasms / chemically induced*
Estradiol Congeners / adverse effects
Estrogen Replacement Therapy / adverse effects*
Estrogens, Conjugated (USP) / adverse effects
Female
Humans
Grant Support
ID/Acronym/Agency:
R35 CA39779/CA/NCI NIH HHS; T32 CA09168/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Estradiol Congeners; 0/Estrogens, Conjugated (USP)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Performance of semiquantitative food frequency questionnaires in international comparisons. Mexico C...
Next Document:  Intercommunity variations in the association between social ties and mortality in the elderly. A com...